Codexis (CDXS) Stock

REDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to five new employees as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 168,400 shares of Codexis common stock and (ii) 39,750 restricted stock units (RSUs) as inducement awards under the company's 2024 Inducement Plan.

REDWOOD CITY, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will attend the Piper Sandler 36th Annual Healthcare Conference, being held December 3-5, 2024, in New York, New York.

—Spotlight Presentation to showcase four routes of synthesis of an approved siRNA therapeutic asset— —Joint poster presentation with Bachem to compare Codexis double-stranded RNA ligase to wild-type enzymes— —Management to host conference call on Thursday, November 14 to discuss data— REDWOOD CITY, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will demonstrate real-world application of its enzymatic synthesis platform via three presentations at the upcoming TIDES Europe annual meeting, being held November 12-14, 2024, in Hamburg, Germany.

REDWOOD CITY, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of an equity grant to one new employee as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employee received an equity award consisting of (i) options to purchase 50,000 shares of Codexis common stock and (ii) 15,000 restricted stock units (RSUs) as an inducement award under the company's 2024 Inducement Plan.

Codexis, Inc. (CDXS) Q3 2024 Earnings Call Transcript

Codexis (CDXS) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.26 per share a year ago.

Oral Presentations to Highlight Results of Customer Collaborations using the ECO Synthesis™ Platform Oral Presentations to Highlight Results of Customer Collaborations using the ECO Synthesis™ Platform

REDWOOD CITY, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to eight new employees as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 350,175 shares of Codexis common stock and (ii) 80,138 restricted stock units (RSUs) as inducement awards under the company's 2024 Inducement Plan. Included in this total are equity awards for Codexis' newly appointed Chief Financial Officer, Georgia Erbez. As part of her inducement to commence employment, Ms. Erbez was granted an option to purchase 300,000 shares of Company common stock and 50,000 shares of RSUs.

REDWOOD CITY, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the third quarter of 2024 on Thursday, October 31, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update.